Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Reactogenicity of Green Signal BCG Vaccine vs SIIL BCG Vaccine in Healthy Children
NCT01250249Phase 3Completed
- Sponsor
- GreenSignal BioPharma
- Start
- Nov 2008
- Primary completion
- Jun 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bcg vaccine in Tuberculosis (TB) (2 arms), sponsored by GreenSignal BioPharma. Primary endpoints: Safety and Reactogenicity at 90 days and Reactogenicity confirmed by PPD administration at 90 days. Started Nov 2008; status: completed.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01250249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01250249.